Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05367856
Other study ID # Chi-BEAM
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 28, 2022
Est. completion date June 1, 2025

Study information

Verified date September 2022
Source Ruijin Hospital
Contact Weili Zhao
Phone +862164370045
Email zwl_trial@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single-center, single-arm clinical study will evaluate the efficacy and safety of Chidamide combined with BEAM Pretreatment Regimen in ASCT treatment of TCL patients.


Description:

T cell lymphoma (TCL) is a group of highly heterogeneous aggressive non-Hodgkin lymphomas with different pathogenesis and clinical prognosis. Despite the survival benefits of Anthracycline-based chemotherapy bridging autologous stem cell transplantation (ASCT), 40% to 50% of TCL patients fail to respond to treatment and relapse or die within a short period of time. In 2021, a multicenter, single-arm, open Phase II trial of Chidamide combined with BEAC as a pretreatment regimen for ASCT of high-risk and relapsed/refractory lymphoma was presented at the ASH Meeting (NCT03629873). The results confirmed that Chidamide has a good prospect in ASCT. Chi-BEAC can increase 2Y-PFS from 55% to 93.3% and 2Y-OS from 58% to 94% in TCL patients after ASCT compared with the historical control group, with good tolerance.In order to provide a new program for improving survival rate, this single-center, single-arm clinical study will evaluate the efficacy and safety of Chidamide combined with BEAM Pretreatment Regimen in ASCT treatment of TCL patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 23
Est. completion date June 1, 2025
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. According to world Health Organization (WHO) classification of disease, T cell lymphoma (excepted IPI 0-1 point ALK+ anaplastic cell lymphoma) was confirmed by histology, CR or PR after first-line treatment; 2. 18= age =65 years old, male or female; 3. ECOG score 0-1; 4. No serious organic lesions in the main organs, meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment) : - White blood cell count =3.0×109/L, absolute neutrophil count =1.5×109/L, Hemoglobin =90g/L, platelet =75×109/L; - Total bilirubin =1.5× upper normal value (ULN); - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5× upper normal value (ULN); - Creatinine clearance was 44-133 mmol/L; 5. No cardiac dysfunction; 6. Life expectancy over 3 months; 7. The subject or his/her legal representative must provide written informed consent prior to conducting a special study examination or procedure. Exclusion Criteria: 1. Central nervous system lymphoma was excluded; 2. Suffering from serious complications or severe infection; 3. A history of other malignant tumors within 5 years, excluding early tumors treated for curative purposes; 4. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.; 5. HBsAg, HCV or HIV positive. Positive HBV and HCV serology is allowed, but DNA/RNA testing must be negative; 6. Laboratory test value during screening; ? Neutrophils <1.5×109/L; Platelet <75×109/L; ? Bilirubin was 1.5 times higher than the normal upper limit, transaminase was 2.5 times higher than the normal upper limit; ? The creatinine level is higher than 1.5 times the upper limit of normal value; 7. Left ventricular ejection fraction ? 50%; 8. Other concurrent and uncontrolled medical conditions considered by the investigator would affect the patient's participation in the study; 9. Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol; 10. Pregnant or lactating women; 11. The researcher judged that the patients were not suitable for this study.

Study Design


Intervention

Drug:
Chidamide combined with BEAM
Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2

Locations

Country Name City State
China Ruijin Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival Progression-free survival was defined as the time from the date of ASCT until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from an cause, whichever occurred first. Baseline up to data cut-off (up to approximately 2 years)
Secondary Overall survival Overall survival was defined as the time from the date of ASCT to the date of death from any cause. Baseline up to data cut-off (up to approximately 2 years)
Secondary Complete remission rate Percentage of participants with complete response was determined on 2014 Lugano criteria. 3 months after the transplantation
Secondary The time of hematopoietic reconstruction The first day of neutrophils =0.5×109/L for 3 consecutive days was the time of successful implantation of granulocytes. Platelet =20.0×109/L for 7 consecutive days and the first day after platelet infusion was considered as the successful time of megakaryocytes implantation. 2 months after the transplantation
Secondary Transplantation-related adverse reactions Transplantation-related adverse reactions are any untoward medical occurrence in a participant which is related to ASCT. Baseline up to data cut-off (up to approximately 4 years)
See also
  Status Clinical Trial Phase
Recruiting NCT04653649 - CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. Phase 1/Phase 2
Not yet recruiting NCT06420076 - Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells Phase 1/Phase 2
Completed NCT01561833 - A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Phase 1
Withdrawn NCT04334174 - Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas Phase 2
Completed NCT00798096 - Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Phase 2
Completed NCT03770000 - Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05996185 - Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma Phase 2
Active, not recruiting NCT01430013 - Trial of Endostar Combined With CHOPT for T Cell Lymphoma Phase 2
Active, not recruiting NCT04502446 - A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) Phase 1
Terminated NCT04973527 - LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Phase 1
Recruiting NCT05230680 - Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) Phase 1/Phase 2
Recruiting NCT03672084 - Allo-HSCT as First-line Consolidation in High-risk PTCL
Recruiting NCT05852028 - A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
Enrolling by invitation NCT03628612 - Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Phase 2
Recruiting NCT00974324 - Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma Phase 2
Completed NCT00877656 - HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Phase 2/Phase 3
Not yet recruiting NCT05772728 - Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) N/A
Completed NCT01300026 - AMG 319 Lymphoid Malignancy FIH Phase 1
Terminated NCT00880867 - Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Phase 1
Recruiting NCT04840875 - Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma Phase 1